Impact of availability of oral hydrocortisone on growth of children with CAH

被引：9

作者：

Khadilkar V.V. ^{[1
,3
]}

Khadilkar A.V. ^{[2
]}

Maskati G.B. ^{[1
]}

机构：

[1] Jehangir Hospital, Deenanath Mangeshkar Hospital, Pune and Bombay Hospital, Bombay

[2] Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, Pune

[3] Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, Pune-411001

来源：

The Indian Journal of Pediatrics | 2005年 / 72卷 / 4期

关键词：

CAH; Hydrocortisone; Prednisolone; Growth;

D O I：

10.1007/BF02724009

中图分类号：

学科分类号：

摘要：

Objectives: 1. To compare growth parameters of patients with Congenital Adrenal Hyperplasia (CAH) managed on Prednisolone (PR) before and on Hydrocortisone (HC) after its availability in India. 2. To compare growth parameters of patients with CAH who have been on treatment with HC since diagnosis with patients managed on PR. Methods: Growth parameters of twelve children (8 m, 4f) with congenital adrenal hyperplasia were retrospectively studied while on treatment with prednisolone (PR) earlier and then hydrocortisone (HC) after it became freely available in India. Results: Patients treated with PR had height Z score of -0.42, weight Z score of -0.45, and height velocity Z score of -2.06. On HC these scores were -0.27, +0.16 and +2.27. Patients treated with HC from the begining had a height Z Score of +0.08, weight Z score of +0.22, and height velocity Z score of +0.68. Conclusion: Hydrocortisone has a less growth effect than prednisolone and patients treated with HC from the beginning showed near normal growth.

引用

页码：301 / 303

页数：2

共 11 条

[1]

Raghupathy P., Disorders of adrenocortical biosynthesis, Edn., pp. 215-228, (2001)

[2]

Agarwal D.K., Agarwal K.N., Upadhyay S.K., Mittal R., Prakash R., Rai S., Physical and sexual growth pattern of affluent Indian children from 5-18 years of age, Indian Pediatr, 29, pp. 1203-1282, (1992)

[3]

Agarwal D.K., Agarwal K.N., Physical growth in Indian affluent children (Birth - 6 years), Indian Pediatr, 31, pp. 377-413, (1994)

[4]

Tanner J.M., Whitehouse R.H., Takaishi M., Standards from birth to maturity for height, weight, height velocity and weight velocity: British children 1965, Arch Dis Child, 41, pp. 454-471, (1966)

[5]

Huma Z., Crawford C., New M.I., Congenital adrenal hyperplasia, Edn., pp. 536-557, (1995)

[6]

DiMartino-Nardi J., Stoner E., O'Connell A., New M.I., The effect of treatment on final height in classical congenital adrenal hyperplasia, Acta Endocrinol Suppl, 279, pp. 305-314, (1986)

[7]

Stikkelbroeck N.M., Van't Hof-Grootenboer, Hermus A.R., Otten B.J., Van't Hof M.A., Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: In early infancy and (pre)puberty, J Clin Endocrinol Metab, 88, pp. 3525-3530, (2003)

[8]

Haynes R.C., Murad F., Adrenocoticotrophic hormone, Adrenocortical steroids and their synthetic analogues, Inhibitors of Adrenocortical steroid biosynthesis, Edn., pp. 1466-1496, (1975)

[9]

Punthakee Z., Legault L., Polychronalos C., Prednisolone in the treatment of adrenal insufficiency: A re-evaluation of relative potency, J Pediatr, 143, pp. 402-405, (2003)

[10]

Einaudi S., Lala R., Corrias A., Matarazzo P., Pagliardini S., Sanctis C., Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, J Pediatr Endocrinol, 6, pp. 173-178, (1993)

← 1 2 →